AdvanCell, an Australia-based radiopharmaceutical company, has raised $112m as investor interest in the radiopharma sector ...

BMY is looking to turn its business around, banking on the strong uptake of new drugs. The recent spate of positive ...

Bristol Myers Squibb Co. closed 1.88% below its 52-week high of $61.10, which the company reached on January 27th.

R Squared Ltd purchased a new position in Bristol-Myers Squibb (NYSE:BMY – Free Report) in the 4th quarter, according to its ...

Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which ...

New heart health biopharmaceutical company Kardigan, which counts among its co-founders the director for Northwestern ...

Researchers at the Johns Hopkins Kimmel Cancer Center have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune ...

At Bristol Myers Squibb (BMS), we believe in the power of science to transform patients’ lives. As a leading global ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...

The recent acquisitions by pharmaceutical giants Johnson & Johnson and Bristol Myers Squibb, worth a combined $28billion, ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Sanofi and Bristol-Myers Squibb have announced they are restructuring their successful long-term alliance. This announcement follows the loss of exclusivity of two key drugs, blood thinner Plavix ...